company background image
TMO

Thermo Fisher Scientific NYSE:TMO Stock Report

Last Price

US$507.19

Market Cap

US$198.7b

7D

-2.6%

1Y

-11.4%

Updated

30 Sep, 2022

Data

Company Financials +
TMO fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance2/6
Financial Health4/6
Dividends0/6

TMO Stock Overview

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide.

Thermo Fisher Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Thermo Fisher Scientific
Historical stock prices
Current Share PriceUS$507.19
52 Week HighUS$672.34
52 Week LowUS$497.83
Beta0.86
1 Month Change-6.99%
3 Month Change-7.49%
1 Year Change-11.44%
3 Year Change73.52%
5 Year Change162.51%
Change since IPO5,489.44%

Recent News & Updates

Sep 28
What Does Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Indicate?

What Does Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Indicate?

Thermo Fisher Scientific Inc. ( NYSE:TMO ) saw significant share price movement during recent months on the NYSE...

Sep 27

Thermo Fisher wins FDA OK of Oncomine Dx Target test to aid in cancer therapy selection

The US FDA has granted approval to Thermo Fisher Scientific's (NYSE:TMO) Oncomine Dx Target test to help determine which cancer patients may benefit from Eli Lilly’s (LLY) Retevmo (selpercatinib). The test is specifically approved for patients with RET-fusion positive advanced or metastatic non-small cell lung cancer, thyroid cancer, and and RET-mutation positive advanced or metastatic medullary thyroid cancer. The Oncomine Dx Target test is a considered a companion diagnostic and next-generation sequencing-based test. Oncomine Dx was already approved to determine treatment for those with non-small cell lung cancer and cholangiocarcinoma and various other oncology treatments. Read why Seeking Alpha contributor Leo Nelissen argued that Thermo Fisher (TMO) is one of the best dividend stocks to own.

Sep 18

Thermo Fisher: One Of The Best Dividend Stocks Money Can Buy

Summary In this article, I start by providing a theoretical foundation that explains why owning low-yielding stocks makes sense. Thermo Fisher is a low-yielding dividend growth stock with the ability to outperform the market with a low-volatility profile. Its product portfolio helps the company to withstand cyclical risks, supply chain woes, and high inflation. Introduction It's time to discuss one of the best stocks money can buy: Thermo Fisher Scientific (TMO). The company does have a yield close to zero percent, yet it's a terrific dividend stock for a number of reasons. The company has a fantastic business model allowing it to withstand severe economic storms, high inflation, and supply chain woes - we are currently dealing with all of this. Thanks to these qualities, the company has a history of strong dividend growth, outperforming capital gains (by a mile), and a low-volatility profile, which makes investing large sums of money quite interesting. I own the company's largest peer Danaher Corp. (DHR) and I'm considering adding TMO as buying quality dividend growth and low volatility is the best way to generate long-term wealth. In July, I covered the company's core business and opportunities as well as its low yield. In this article, I will incorporate current events including comments from the Morgan Stanley Healthcare conference that show that TMO is well-equipped against challenges like supply chain difficulties, high inflation, and slowing economic growth. So, let me walk you through my thoughts! Starting with some theoretical background. Why Dividend Growth Makes Sense - Despite A Low Yield I always like to combine companies with a macro thesis or a theoretical background. Especially when covering very low-yielding dividend stock, I believe it's important to provide the necessary background. Thermo Fisher is currently paying a $0.30 per share per quarter dividend. That's $1.20 per year. In order to get that, investors need to hold a share, which is currently trading at $540. That's more expensive than a PlayStation 5, resulting in a yield of just 0.22%. In other words, a $10,000 investment would end up paying $22 per year. It is clear that Thermo Fisher isn't the stock you want to buy when looking for high income - or income in general. Personally, I like buying a decent yield. However, I also like owning high-quality stocks that let me sleep like a baby, especially when the market is volatile and bombed my uncertainty and macroeconomic issues, which is currently the case. While I will get into that in this article, let's look into the reasons why dividends are important in the first place. Morgan Stanley hit the nail on the head when it found that dividend payers return way more than non-dividend payers. A recent study by FactSet shows that dividend-paying stocks outperform their non-paying counterparts by a dramatic amount. From 1991 through 2015, non-dividend paying stocks earned just +4.18% return per year while dividend paying stocks significantly outperformed with a +9.7% average annual return. Essentially, this is caused by dividends being a "stamp of approval". Operating a business is hard. Distributing cash is harder. Doing it consistently while growing dividends is even harder. Companies paying a dividend show that they are able to compete while letting shareholders benefit in the process. That's great quality and something shareholders can rely on, especially when recessions cause uncertainty to skyrocket. Moreover, dividend growth stocks often protect dividends against inflation, which adds to the "quality" aspect of an investment. In a 2022 paper, Hartford Funds compared dividend stocks to Volvo cars, which I think was quite fitting: Dividend-paying stocks are like the Volvos of the investing world. They’re not fancy at first glance, but they have a lot going for them when you look deeper under the hood. The same research paper showed that both dividend payers and dividend growers outperformed the equal-weight S&P 500 index by a mile on a long-term basis. Moreover, the paper mentions the "quality" aspect in the text above the chart below. Being a dividend grower is basically a sign of strong fundamentals. Also, and this is important, companies that pay dividends need to be more careful with their cash flows. They need to make smarter decisions to protect the dividend and to make sure that investments allow for future dividend growth. It's truly a fantastic controlling mechanism, I think. Hartford Funds Moreover, the quality aspect protects investors a bit during bear markets. Don't get me wrong, most dividend stocks will also suffer when markets tank. However, odds are they do better as investors will rather sell non-dividend paying companies or companies that struggle, in general, when re-risking their portfolios. These companies are often non-dividend paying companies. As the chart below shows, both dividend growth and high-yield stocks outperform the broader market while doing it with less volatility. While I do own a number of rather volatile stocks, I am a big believer in investing in low volatility because it tends to provide outperformance without a lot of drama. This is especially important when selling investments somewhere in the future. Low-volatility stocks are much more reliable. Vanguard Now, you know why I cannot stop talking about low-yielding dividend stocks. Thermo Fisher - High-Quality Dividends Before we dive into financial numbers and whatnot, let me show you that Thermo Fisher has indeed proven to be a source of low-volatility outperformance. Going all the way back to 1988, the stock has returned 15.9% per year. This beats the S&P 500 by more than 500 basis points. The standard deviation was 27.9%, which is rather high compared to the S&P 500. Yet, TMO still beat the S&P 500 on a volatility-adjusted basis (Sharpe/Sortino ratios). Portfolio Visualizer Moreover, the somewhat high volatility of TMO was caused by the company being somewhat young in the 20 years prior to the 2000s. Over the past 20 years, the company has returned 16.6% per year. The standard deviation has come down to 22.1%. Even the worst drawdown was "just" 44%, that's more than 600 basis points better than the S&P 500's performance during the Great Financial Crisis. Portfolio Visualizer With that said, the "worst" thing about TMO is its yield as we already briefly discussed, yet it's also the only thing that might bother a potential investor. Looking at the Seeking Alpha dividend scorecard, we see that the company scores extremely high on dividend safety and dividend growth compared to its healthcare sector peers. Seeking Alpha The 10-year average annual dividend growth rate is 16.1%, which is impressive. These are the most "recent" hikes: February 2022: 15.0% February 2021: 18.0% February 2020: 16.0% TMO Dividend data by YCharts The payout ratio is rather low, which explains why dividend safety is scoring so high. Using $18.80 in earnings per share over the past four quarters and the aforementioned $1.20 annual dividend, the payout ratio is a mere 6.4%. A Top Tier Business Model With a sub-10% payout ratio, Thermo Fisher obviously has other priorities than to get rid of its cash through dividends. Below, I listed some of the ways to get rid of cash: stock repurchases (also issuance of stock), common dividends paid, and cash acquisitions. TIKR.com Thermo Fisher has a genius business model, which is based on high free cash flow generation, which is then used to buy more growth (acquisitions), which then generates more free cash flow used to repay debt. The graph below shows that spikes in net debt always lead to lower debt levels in the years that follow as free cash flow is growing rapidly. Between 2016-2024E, free cash flow is growing by 15.5% CAGR. That's truly impressive. Next year, the implied FCF yield is 4.0%, which is rather high. This allows for a quick debt reduction to $22.1 billion according to analyst estimates. That would imply a 1.7x net leverage multiple. Hence, it is no surprise that the company has a BBB+ debt rating. I believe it won't take long until the company enters the A-range. TIKR.com With that said, let's dive a bit deeper as I haven't even explained what Thermo Fisher does exactly - almost 1,300 words into this article. Thermo Fisher is basically a healthcare supplier. It sells equipment for Life Science Solutions, Specialty Diagnostics, Analytical Instruments, Laboratory Products, and Biopharma Services. For example, in its biggest segment, Life Sciences Solutions, the company: [...] provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes four primary businesses – Biosciences, Genetic Sciences, Clinical Next-Generation Sequencing, and BioProduction. With more than 100,000 employees, the company is a powerhouse in the industry with what it believes is a $225 billion total addressable market. The company sees between 4% to 6% in annual long-term growth. Achieving these growth numbers would be a good deal. However, TMO is growing by 7% to 9% in this industry - organically! This is thanks to its innovative products, experienced sales force, and a great relationship with customers. Using Seeking Alpha's handy overview of historical annual growth rates (including acquired growth), we see that the company has grown its top line by more than 13% per year over the past 10 years. Thanks to higher margins, this resulted in roughly 18% average annual EBITDA growth and close to 19% in annual net income growth. The earnings per share growth rate was slightly lower as TMO does not engage in net buybacks. Gross buybacks are offset by stock-based compensation and M&A activities. Seeking Alpha With this in mind, let me show you some comments from the recent Morgan Stanley Annual Global Healthcare Conference where Thermo Fisher mentioned a few things that are extremely important given ongoing supply chain problems, slowing global growth, and high inflation. First of all, the company is extremely resilient. This is based on its own abilities and the fact that healthcare is anti-cyclical to a large extent. During the Great Financial Crisis, sales in TMO's market fell only 3%. The rebound afterward was much stronger. Moreover, the company's product mix has become much more favorable compared to almost 14 years ago: When I think about how the company, how we've evolved our mix by executing our strategy, the company is -- has a more favorable set of end markets than we did back at the end of the 2000s. And today, pharmaceutical and biotech which is the least economically exposed end market, represents just under 60% of our core revenue. And back then, it was about 1/4 of our core revenue. And our consumables and service business is about 85% of our revenue. Back then, it was about 2/3 of our revenue. So the company's mix has evolved and that positions us to navigate whatever the world throws at us. Moreover, in Europe, the company still sees positive organic growth despite severe economic challenges. It has also gotten rid of natural gas in its facilities, which will be a huge benefit if rationing is applied during the winter months. The same goes for the (still ongoing) shortages in semiconductors, electronic parts, and related. The company was able to maintain strong organic growth as it has great relationships with suppliers. After all, the company is a giant with preferred customer status at many suppliers - which is something I assume given the results. This basically means that when inventories fall, suppliers provide the best supplies to their preferred customers. These are mainly large corporations with innovation and pricing power. While this data isn't public, I assume that TMO has this buyer status with all core suppliers. The company also has strong pricing power. According to the company: And in a given year, we would get 50 to 100 basis points of price every year. And that's part of our economic formula in terms of high single-digit organic growth and you say you're getting 0.75 point on price. So that's the norm.

Shareholder Returns

TMOUS Life SciencesUS Market
7D-2.6%-1.9%-2.5%
1Y-11.4%-31.9%-23.2%

Return vs Industry: TMO exceeded the US Life Sciences industry which returned -31.4% over the past year.

Return vs Market: TMO exceeded the US Market which returned -21.5% over the past year.

Price Volatility

Is TMO's price volatile compared to industry and market?
TMO volatility
TMO Average Weekly Movement4.1%
Life Sciences Industry Average Movement9.9%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: TMO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: TMO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1956130,000Marc Casperhttps://www.thermofisher.com

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.

Thermo Fisher Scientific Fundamentals Summary

How do Thermo Fisher Scientific's earnings and revenue compare to its market cap?
TMO fundamental statistics
Market CapUS$198.71b
Earnings (TTM)US$7.44b
Revenue (TTM)US$42.82b

26.7x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TMO income statement (TTM)
RevenueUS$42.82b
Cost of RevenueUS$22.84b
Gross ProfitUS$19.98b
Other ExpensesUS$12.54b
EarningsUS$7.44b

Last Reported Earnings

Jul 02, 2022

Next Earnings Date

n/a

Earnings per share (EPS)18.99
Gross Margin46.66%
Net Profit Margin17.37%
Debt/Equity Ratio71.2%

How did TMO perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

6%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is TMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TMO?

Other financial metrics that can be useful for relative valuation.

TMO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA17.8x
PEG Ratio2.4x

Price to Earnings Ratio vs Peers

How does TMO's PE Ratio compare to its peers?

TMO PE Ratio vs Peers
The above table shows the PE ratio for TMO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average29.1x
DHR Danaher
30.3x7.4%US$187.9b
A Agilent Technologies
27.1x10.4%US$36.0b
IQV IQVIA Holdings
29.1x18.4%US$33.8b
MTD Mettler-Toledo International
29.7x7.4%US$24.4b
TMO Thermo Fisher Scientific
26.7x11.1%US$198.7b

Price-To-Earnings vs Peers: TMO is good value based on its Price-To-Earnings Ratio (26.7x) compared to the peer average (29.1x).


Price to Earnings Ratio vs Industry

How does TMO's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: TMO is expensive based on its Price-To-Earnings Ratio (26.7x) compared to the US Life Sciences industry average (23.6x)


Price to Earnings Ratio vs Fair Ratio

What is TMO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TMO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.7x
Fair PE Ratio30.4x

Price-To-Earnings vs Fair Ratio: TMO is good value based on its Price-To-Earnings Ratio (26.7x) compared to the estimated Fair Price-To-Earnings Ratio (30.4x).


Share Price vs Fair Value

What is the Fair Price of TMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TMO ($507.19) is trading below our estimate of fair value ($954.64)

Significantly Below Fair Value: TMO is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Thermo Fisher Scientific forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TMO's forecast earnings growth (11.1% per year) is above the savings rate (1.9%).

Earnings vs Market: TMO's earnings (11.1% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: TMO's earnings are forecast to grow, but not significantly.

Revenue vs Market: TMO's revenue (5.1% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: TMO's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TMO's Return on Equity is forecast to be high in 3 years time (20.8%)


Discover growth companies

Past Performance

How has Thermo Fisher Scientific performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


30.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TMO has high quality earnings.

Growing Profit Margin: TMO's current net profit margins (17.4%) are lower than last year (22.5%).


Past Earnings Growth Analysis

Earnings Trend: TMO's earnings have grown significantly by 30.3% per year over the past 5 years.

Accelerating Growth: TMO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TMO had negative earnings growth (-13.4%) over the past year, making it difficult to compare to the Life Sciences industry average (15.6%).


Return on Equity

High ROE: TMO's Return on Equity (17.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Thermo Fisher Scientific's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: TMO's short term assets ($18.1B) exceed its short term liabilities ($11.0B).

Long Term Liabilities: TMO's short term assets ($18.1B) do not cover its long term liabilities ($37.1B).


Debt to Equity History and Analysis

Debt Level: TMO's net debt to equity ratio (66.8%) is considered high.

Reducing Debt: TMO's debt to equity ratio has reduced from 75.8% to 71.2% over the past 5 years.

Debt Coverage: TMO's debt is well covered by operating cash flow (29.2%).

Interest Coverage: TMO's interest payments on its debt are well covered by EBIT (19.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Thermo Fisher Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.24%

Current Dividend Yield

Dividend Yield vs Market

Thermo Fisher Scientific Dividend Yield vs Market
How does Thermo Fisher Scientific dividend yield compare to the market?
SegmentDividend Yield
Company (Thermo Fisher Scientific)0.2%
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Life Sciences)0.3%
Analyst forecast in 3 Years (Thermo Fisher Scientific)0.3%

Notable Dividend: TMO's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.66%).

High Dividend: TMO's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (4.7%).


Stability and Growth of Payments

Stable Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: TMO is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: TMO is not paying a notable dividend for the US market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Marc Casper (54 yo)

12.92yrs

Tenure

US$21,234,358

Compensation

Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M...


CEO Compensation Analysis

Marc Casper's Compensation vs Thermo Fisher Scientific Earnings
How has Marc Casper's remuneration changed compared to Thermo Fisher Scientific's earnings?
DateTotal Comp.SalaryCompany Earnings
Jul 02 2022n/an/a

US$7b

Apr 02 2022n/an/a

US$8b

Dec 31 2021US$21mUS$2m

US$8b

Oct 02 2021n/an/a

US$9b

Jul 03 2021n/an/a

US$9b

Apr 03 2021n/an/a

US$8b

Dec 31 2020US$26mUS$2m

US$6b

Sep 26 2020n/an/a

US$5b

Jun 27 2020n/an/a

US$4b

Mar 28 2020n/an/a

US$4b

Dec 31 2019US$19mUS$2m

US$4b

Sep 28 2019n/an/a

US$4b

Jun 29 2019n/an/a

US$4b

Mar 30 2019n/an/a

US$3b

Dec 31 2018US$19mUS$1m

US$3b

Sep 29 2018n/an/a

US$3b

Jun 30 2018n/an/a

US$2b

Mar 31 2018n/an/a

US$2b

Dec 31 2017US$22mUS$1m

US$2b

Sep 30 2017n/an/a

US$2b

Jul 01 2017n/an/a

US$2b

Apr 01 2017n/an/a

US$2b

Dec 31 2016US$18mUS$1m

US$2b

Oct 01 2016n/an/a

US$2b

Jul 02 2016n/an/a

US$2b

Apr 02 2016n/an/a

US$2b

Dec 31 2015US$16mUS$1m

US$2b

Compensation vs Market: Marc's total compensation ($USD21.23M) is above average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TMO's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: TMO's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TMO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NYSE:TMO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Aug 22SellUS$486,156Jim ManziIndividual814US$597.98
02 May 22SellUS$108,872Debora SparIndividual200US$544.36
01 Mar 22SellUS$3,301,890Michel LagardeIndividual6,100US$541.52
14 Feb 22SellUS$845,925Jim ManziIndividual1,500US$563.95

Ownership Breakdown

What is the ownership structure of TMO?
Owner TypeNumber of SharesOwnership Percentage
State or Government175,7510.04%
Private Companies309,0520.08%
Individual Insiders642,5040.2%
General Public42,622,68810.9%
Institutions348,038,96788.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 50.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.11%
The Vanguard Group, Inc.
31,760,066$16.1b0.96%0.38%
7.77%
BlackRock, Inc.
30,433,250$15.4b0.45%0.39%
5.84%
Capital Research and Management Company
22,879,376$11.6b-0.52%0.82%
4.09%
State Street Global Advisors, Inc.
16,023,439$8.1b-1.2%0.46%
3.25%
T. Rowe Price Group, Inc.
12,746,817$6.5b-12.28%0.78%
2.71%
Massachusetts Financial Services Company
10,599,890$5.4b-4.34%1.43%
2.39%
FMR LLC
9,348,539$4.7b-4.24%0.45%
1.69%
Geode Capital Management, LLC
6,640,467$3.4b1.51%0.45%
1.12%
Morgan Stanley, Investment Banking and Brokerage Investments
4,382,088$2.2b3.99%0.45%
1.06%
Norges Bank Investment Management
4,172,455$2.1b0%0.29%
1.03%
UBS Asset Management
4,042,255$2.1b-1.61%0.4%
1.02%
Northern Trust Global Investments
3,979,508$2.0b-4.78%0.42%
1.01%
J.P. Morgan Asset Management, Inc.
3,956,740$2.0b-0.13%0.38%
1%
Morgan Stanley Investment Management Inc.
3,923,526$2.0b-4.36%1.58%
0.98%
PRIMECAP Management Company
3,852,452$2.0b-2.16%1.82%
0.91%
Eaton Vance Management
3,577,187$1.8b3.04%0.7%
0.87%
BNY Mellon Asset Management
3,401,673$1.7b0.61%0.4%
0.76%
Wellington Management Group LLP
2,994,345$1.5b-0.71%0.28%
0.72%
Pictet Asset Management Limited
2,836,355$1.4b-2.87%1.32%
0.7%
ClearBridge Investments, LLC
2,746,462$1.4b-0.98%1.31%
0.7%
Legal & General Investment Management Limited
2,726,223$1.4b-0.94%0.42%
0.66%
Managed Account Advisors LLC
2,592,777$1.3b-0.27%0.38%
0.6%
Fisher Asset Management, LLC
2,340,814$1.2b3.72%0.89%
0.57%
Dimensional Fund Advisors LP
2,236,694$1.1b-4.44%0.29%
0.54%
Brown Advisory Incorporated
2,107,591$1.1b-9.24%1.91%

Company Information

Thermo Fisher Scientific Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Thermo Fisher Scientific Inc.
  • Ticker: TMO
  • Exchange: NYSE
  • Founded: 1956
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$198.711b
  • Shares outstanding: 391.79m
  • Website: https://www.thermofisher.com

Number of Employees


Location

  • Thermo Fisher Scientific Inc.
  • 168 Third Avenue
  • Waltham
  • Massachusetts
  • 2451
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TMONYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1980
TN8DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1980
TN8XTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1980
TMO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1980
0R0HLSE (London Stock Exchange)YesCommon StockGBUSDJan 1980
TN8ETLX (Eurotlx)YesCommon StockITEURJan 1980
TMOFWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1980
TMOBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1980
TMOS34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 48 REP 1 COMBRBRLApr 2016
TMOBASE (Buenos Aires Stock Exchange)CEDEAR EAC 22 REP 1(USD)ARARSApr 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/07/02
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.